Predicting heart and blood vessel disease risk in type 2 diabetes using immune-cell computer tools
ASCVD risk assessment in T2DM facilitated by novel computational immunology programs
['FUNDING_R01'] · UNIVERSITY OF CONNECTICUT SCH OF MED/DNT · NIH-11258020
This project uses new computer tools to read immune cell behavior and predict heart and blood vessel disease risk in people with type 2 diabetes.
Quick facts
| Phase | ['FUNDING_R01'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF CONNECTICUT SCH OF MED/DNT (nih funded) |
| Locations | 1 site (FARMINGTON, UNITED STATES) |
| Trial ID | NIH-11258020 on ClinicalTrials.gov |
What this research studies
From my perspective as a patient, researchers will study circulating immune cells, especially monocytes, to see how they become cholesterol-filled 'foam' cells that harm arteries. They will apply newly developed computational immunology and cell-function annotation tools to patterns in blood samples and patient data. The team will combine lab analyses and existing clinical information to build prediction models tailored for people with type 2 diabetes. The goal is to find immune-cell signatures that signal higher ASCVD risk and point to ways to prevent it.
Who could benefit from this research
Good fit: Adults with type 2 diabetes who are willing to provide blood samples or share medical records for research would be the best candidates.
Not a fit: People without type 2 diabetes, or those with already advanced cardiovascular disease, are unlikely to gain direct benefit from this risk-prediction work.
Why it matters
Potential benefit: If successful, this could improve how we predict and prevent heart attacks and strokes in people with type 2 diabetes.
How similar studies have performed: Existing ASCVD risk models have done poorly in type 2 diabetes, and using computational immune-cell profiling is a newer approach with limited prior clinical validation.
Where this research is happening
FARMINGTON, UNITED STATES
- UNIVERSITY OF CONNECTICUT SCH OF MED/DNT — FARMINGTON, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: ZHOU, BEIYAN — UNIVERSITY OF CONNECTICUT SCH OF MED/DNT
- Study coordinator: ZHOU, BEIYAN
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Adult-Onset Diabetes Mellitus, Atherosclerotic Cardiovascular Disease